Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Operations: 2013-2024

Historic Cash from Operations for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to -$148.6 million.

  • Seres Therapeutics' Cash from Operations rose 106.36% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.1 million, marking a year-over-year increase of 85.34%. This contributed to the annual value of -$148.6 million for FY2024, which is 26.63% down from last year.
  • According to the latest figures from FY2024, Seres Therapeutics' Cash from Operations is -$148.6 million, which was down 26.63% from -$117.4 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Cash from Operations registered a high of $6.7 million during FY2021, and its lowest value of -$228.8 million during FY2022.
  • Its 3-year average for Cash from Operations is -$164.9 million, with a median of -$148.6 million in 2024.
  • As far as peak fluctuations go, Seres Therapeutics' Cash from Operations soared by 107.14% in 2021, and later crashed by 3,521.29% in 2022.
  • Over the past 5 years, Seres Therapeutics' Cash from Operations (Yearly) stood at -$93.6 million in 2020, then spiked by 107.14% to $6.7 million in 2021, then tumbled by 3,521.29% to -$228.8 million in 2022, then skyrocketed by 48.71% to -$117.4 million in 2023, then dropped by 26.63% to -$148.6 million in 2024.